UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Recent developments in the treatment of systemic lupus erythematosus
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Journal Article
  • Authors:
    Huertas CM, Salvador F, Isenberg D
  • Publication date:
    01/02/2012
  • Pagination:
    14, 17
  • Journal:
    European Musculoskeletal Review
  • Volume:
    7
  • Issue:
    1
  • Status:
    Published
  • Print ISSN:
    1754-5072
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disorder, characterised by pathogenic antibodies produced by hyper-reactive B cells recognising self-antigens, which cause organ damage via immune complex formation, complement activation and direct effects on cells. It can be a life-threatening disease when major organs, such as the kidneys, are affected. Lupus is approximately 10 times more common in women than in men. The majority of lupus patients will develop their disease between the ages of 15 and 50. If not treated promptly, a significant proportion of patients, especially those with more aggressive disease, accumulate irreversible damage. Accelerated atherosclerosis and infections represent a major challenge in the management of the disease. Conventional drug treatment options range from non-steroidal anti-inflammatory drugs to immunosuppressive therapies. Understanding the disease pathogenesis has led to the use of targeted therapies, notably biological agents. This article will focus on the traditional immunosuppressive therapies used in the treatment of SLE and the biological therapies recently developed. © TOUCH BRIEFINGS 2012.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by